Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.

Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

Atai Life Sciences Logo White

ATAI Life Sciences

Beckley Psytech Company Profile

Beckley Psytech

Better Plant Sciences Company Profile

Better Plant Sciences (PLNT)

CaaMTech Company Profile

CaaMTech

Champignon Brands Company Profile

Champignon Brands Inc. (SHRM)

Compass Pathways Company Profile

COMPASS Pathways (CMPS)

Cybin Company Profile

Cybin Inc.

Eleusis Company Profile

Eleusis

Entheon Biomedical

Field Trip FTRP Company Profile

Field Trip (FTRP)

Havn Life Company Profile

Havn Life (HAVN)

Hollister Biosciences Company Profile

Hollister Biosciences (HOLL)

MagicMed Company Profile

MagicMed Industries

MindMed MMED Company Profile

MindMed (MMED)

Mydecine Innovations Company Profile

Mydecine Innovations Group (MYCO)

Numinus Company Profile

Numinus (NUMI)

Revive Therapeutics Company Profile

Revive Therapeutics Ltd. (RVV)

Your Pα+ account

Sign in

Quick Links

  • InsightsOpens in a new tab
  • JobsOpens in a new tab
  • DataOpens in a new tab
  • Subscribe to Pα+Opens in a new tab
  • ContactOpens in a new tab
  • Oregon Psilocybin Services Tracker: Q1 2025July 4, 2025
    As the first cut of data from Oregon's psilocybin program becomes available, we take a deep dive into emerging trends through various data visualisations and analysis. This marks the first instalment of our new Oregon Psilocybin Services Tracker, which will produce analysis of each cut of data as it is released. ∎
  • Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of PsychedelicsJuly 3, 2025
    Psychedelic Alpha’s Charles Bliss speaks with Chris Timmermann, Research Fellow in Neuroscience, Meditation and Psychedelics at University College London, about why understanding and integrating psychedelic experiences may be just as vital for personal growth as for treating mental illness.
  • Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing ModelJuly 1, 2025
    We cover Beckley Psytech and atai Life Sciences' conference call this morning, where company executives provided further details on the Phase 2b readout of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression and took aim at their closest competitor's model.
  • Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b StudyJuly 1, 2025
    This morning, Beckley Psytech shares topline data from its Phase 2b study of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD). The study, the largest of the drug to date, printed positive results, with a significant and rapid antidepressant effect and favourable safety profile. Here, we take a closer look at the results and share our quick-take analysis with reference to GH Research’s similar Phase 2b study.
  • Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 PlansJuly 1, 2025
    Psychedelic Alpha’s Josh Hardman sits down with Beckley Psytech CEO Cosmo Feilding-Mellen and Chief Scientific and Medical Officer Rob Conley to discuss today’s topline results from the company’s Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD).

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More